A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

• ABI-1179 (Drug): Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
• ABI-1179 Placebo (Drug): Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)

Primary outcomes

• Area Under the Plasma Concentration Time Curve, (AUC) of ABI-1179 [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.]
• Maximum Observed Plasma Concentration (Cmax) of ABI-1179 [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.]
• Time to Cmax (Tmax) of ABI-1179 [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.]
• Apparent Terminal Elimination Half Life ( t 1/2) ABI-1179 [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.]
• Apparent Systemic Clearance (CL/F) of ABI-1179 [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.]
• Apparent Volume of Distribution (Vz/F) of ABI-1179 [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.]
• Dose normalized AUCs and Cmax of ABI-1179 [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing. MAD Cohorts: before and at pre-specified time points up to 8 hours after dosing.]
• Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AE's and abnormal laboratory results. [Up to 56 days after last dose.]

Secondary outcomes

• SAD Cohorts: Comparison of Plasma AUC between fasted and fed treatments [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• SAD Cohorts: Comparison of plasma Cmax between fasted and fed treatments [SAD Cohorts: before and at pre-specified timepoints up to 144 hours after dosing.]
• MAD Cohort: If applicable comparison of plasma AUC and Cmax with and without loading doses [MAD Cohorts At pre-specified timepoints from Days 8 to 36]
• MAD Cohorts: Difference in viral shedding rate (number of anogenital swabs positive for HSV-2 DNA/total number of swabs) across treatments. [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: in mean and median HSV-2 DNA copies/ml for swab samples positive for HSV-2 DNA across treatments [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: Difference in the proportion of swab samples with HSV-2 DNA>4log10 copies/mL across treatments (number of swabbing samples with HSV-2 DNA >4 log10 copies/mL / total number of swabs obtained). [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: Difference in number of shedding episodes during the swabbing period across treatments. [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: Difference in duration of shedding episodes during the swabbing period across treatments. [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: Difference in the subclinical shedding rate (number of swabs positive for HSV-2 DNA in the absence of lesions/total number of swabs in the absence of lesions) across treatments. [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: Difference in the lesion rate during the swabbing period across treatments. [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: Difference in lesion duration during the swabbing period across treatments [MAD Cohorts: At pre-specified time points from Days 8 to 36.]
• MAD Cohorts: Difference in the recurrence rate (number of reappearances of lesions during the swabbing period/total days assessed) across treatments. [MAD Cohorts: At pre-specified time points from Days 8 to 36.]

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Part A: Inclusion Criteria:

* Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2
* In good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results.
* Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day-1 or Day 1 (predose).
* Agreement to comply with protocol-specified contraceptive requirements.

Part B: Inclusion Criteria:

* Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2
* Other than HSV infection, is in good health (as determined by the investigator) based on medical history, physical examination, ECG, and clinical laboratory results.
* Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 (predose).
* Agreement to comply with protocol-specified contraceptive requirements

Part A and B: Exclusion Criteria:

* Current infection of human immunodeficiency virus (HIV), hepatitis B virus, (HBV), hepatitis C virus (HCV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV).
* History of any illness that, in the opinion of the Investigator, might confound the results of the study, pose an additional risk in administering study drug to the subject, or condition known to interfere with the absorption /distribution/ elimination of drugs.
* History of any significant drug-related allergic reactions such as anaphylaxis, Stevens-Johnson Syndrome, urticaria, or multiple drug allergies.
* History of persistent alcohol abuse or illicit drug abuse within 3 years prior to screening.
* Has participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 half-lives before screening, whatever is longer.